Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03912259 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab
DRUG: Placebo
DRUG: Emollient (moisturizer)

Sponsor

Sanofi

Collaborators

[object Object]